Benign prostatic hyperplasia (BPH), or enlarged prostate, affects millions of older men, but a surge of innovative treatments approved and in development could soon give patients more choices than ever before. As of 2026, more than 10 major pharmaceutical and medical device companies are actively developing over 10 new BPH therapies, with several already receiving FDA clearance and others in late-stage clinical trials . These emerging options range from minimally invasive implants to novel drug formulations, offering men alternatives to traditional approaches.

What Is Benign Prostatic Hyperplasia and Why Does It Matter?

Benign prostatic hyperplasia is a common condition in which the prostate gland, which surrounds the urethra (the tube that carries urine from the bladder), gradually enlarges with age. This enlargement can restrict urine flow and cause lower urinary tract symptoms (LUTS) like frequent urination, weak stream, and incomplete emptying. While BPH is not cancer and not life-threatening, it significantly impacts quality of life for millions of men, particularly those over 45 .

Which New BPH Treatments Have Already Been Approved?

The FDA has recently cleared several groundbreaking devices designed to treat BPH symptoms without traditional surgery. In December 2025, the FDA approved the Zenflow Spring Implant and Delivery System, a first-line interventional therapy that widens the urethra while maintaining natural anatomy through a spring-like implant . Notably, this treatment can be performed in an outpatient setting using the Zenflow Spring Scope, which received FDA 510(k) clearance earlier in 2025.

In January 2026, Butterfly Medical announced successful completion of its international pivotal clinical trial for the Butterfly Prostatic Retraction Device, another first-line interventional therapy designed to treat BPH . Additionally, in March 2026, Prodeon Medical obtained FDA 510(k) clearance for the Urocross Expander System, a temporary implant technology specifically designed to treat lower urinary tract symptoms linked to BPH .

In April 2025, the investigational ProVee Urethral Expander System met all safety and effectiveness endpoints in a Phase 3 study presented at the American Urological Association Annual Meeting . The ProVIDE trial included men aged 45 and older with moderate-to-severe symptomatic BPH, and participants were randomly assigned in a 2-to-1 ratio to receive either ProVee or a sham procedure to evaluate the device's true effectiveness.

What Types of Therapies Are in Development?

The BPH treatment pipeline includes a diverse range of approaches targeting different mechanisms of action. Companies worldwide are developing therapies across multiple categories, including small molecule drugs, recombinant fusion proteins, peptides, and gene therapy candidates . These products are being administered through various routes, including oral medications, intravenous injections, subcutaneous injections, parenteral delivery, and topical applications.

• Oral Medications: Companies like Eli Lilly, Astellas Pharma, and RECORDATI GROUP are developing oral therapies including Tadalafil, ASP4901, and Silodosin, which work by relaxing smooth muscle in the prostate and bladder neck.
• Minimally Invasive Implants: Devices such as AIV007 (AiViva BioPharma), RT-310 (Resurge Therapeutics), and NX-1207 (Nymox Corporation) represent a new class of interventional therapies designed to provide symptom relief without major surgery.
• Advanced Pharmaceutical Approaches: Emerging therapies like Teverelix trifluoroacetate (Antev), Fexapotide (Nymox Pharmaceutical), and GI198745 (GlaxoSmithKline) employ novel mechanisms including hormone modulation and targeted protein delivery.
• Robotic and Ultrasound Technologies: EDAP TMS SA initiated a Phase 1/2 study in October 2024 assessing Focal One robotic high-intensity focused ultrasound (HIFU) for BPH treatment, representing a cutting-edge non-invasive approach.

How to Navigate Your BPH Treatment Options

• Consult Your Urologist Early: If you experience symptoms like frequent urination, weak urine stream, or incomplete bladder emptying, schedule an appointment with a urologist who can assess your symptoms using the International Prostate Symptom Score (IPSS) and recommend appropriate treatment based on severity.
• Understand Your Symptom Severity: BPH treatments are typically recommended for men with moderate-to-severe symptoms (IPSS score of 13 or higher). Mild symptoms may be managed with watchful waiting or lifestyle modifications, so understanding your baseline is crucial.
• Explore Minimally Invasive Options First: The newest FDA-approved treatments like Zenflow and ProVee are designed as first-line interventional therapies, meaning they can be considered before traditional surgery and often performed in outpatient settings with faster recovery times.
• Ask About Clinical Trial Availability: If you're interested in cutting-edge treatments, ask your urologist whether you might qualify for ongoing clinical trials, which provide access to investigational therapies and close medical monitoring.
• Consider Your Lifestyle and Recovery Preferences: Outpatient procedures like the Zenflow Spring Implant may appeal to men who want minimal downtime, while oral medications might suit those preferring non-invasive approaches, though they may take longer to show results.

What Companies Are Leading the BPH Innovation Race?

Major pharmaceutical and medical device manufacturers are heavily invested in BPH treatment development. Companies actively working on new therapies include AiViva BioPharma, Chong Kun Dang, EMS, Urotronic Inc., Resurge Therapeutics, Antev, Nymox Pharmaceutical, GlaxoSmithKline, Dongkook Pharmaceutical, RECORDATI GROUP, Astellas Pharma, Eli Lilly, Sophiris Bio Corp, Bayer, Warner Chilcott, QLT Inc., NeoTract Inc., and Xintian Pharmaceutical . This competitive landscape suggests continued innovation and potentially more treatment options in the coming years.

When Can Men Expect These New Treatments to Become Available?

Several therapies are already available or nearing availability. The Zenflow Spring Implant is currently approved and available, while other devices like ProVee are completing Phase 3 trials and moving toward FDA approval. Many oral medications and other interventional devices are in mid-to-late stage clinical development, suggesting they could reach the market within the next 1 to 3 years . Early-stage candidates and pre-clinical therapies may take longer, but the robust pipeline indicates a steady stream of new options will continue to emerge.

The expansion of BPH treatment options represents a significant shift in men's health care. Rather than facing a choice between watchful waiting and invasive surgery, men with enlarged prostate symptoms now have access to minimally invasive devices, novel medications, and advanced technologies. If you're experiencing lower urinary tract symptoms, discussing these emerging options with your urologist could help you find a treatment approach that fits your lifestyle and health goals.